Gwen A. Melincoff

Gwen A. Melincoff (board member) discloses dealings in 3 companies, chiefly Collegium Pharmaceutical, Inc, Protalix BioTherapeutics, Inc. and Soleno Therapeutics Inc. The record holds 9 filings, for trades running from 24 May 2018 to 3 September 2025.

The open-market record is one-sided, with 1 purchase worth €14k and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 8 share grants.

Most recently, on 4 September 2025, the filings show a share grant in Protalix BioTherapeutics, Inc. The most recent open-market purchase was published on 20 November 2019, 2,529 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.